Citable filing context
EMR's research view summarizes recent SEC filing context, starting with earnings from Aug 4, 2026.
| Filed | Item | Context |
|---|---|---|
| Aug 4, 2026 | earnings | Emerson reported Q3 2026 net sales of $4.87B, up 7%, and raised its full-year outlook. |
| Feb 13, 2026 | debt_offering | Emerson Electric Co. entered into a $2 billion 364-day unsecured credit facility on February 10, 2026. |
| Feb 6, 2026 | other | Emerson Electric Co. held its 2026 Annual Meeting of Shareholders on February 3, 2026. |
| Aug 4, 2026 | Guidance: adjusted_earnings_per_share | not reported to 6.55 |
| Aug 4, 2026 | Guidance: earnings_per_share | not reported to 4.89 |
| Aug 4, 2026 | Guidance: free_cash_flow | not reported to 3.60 |
| Aug 4, 2026 | mda_quarterly | Emerson reported strong third-quarter fiscal 2026 results, with net sales of $4.9 billion, a 7% increase year-over-year. Underlying sales grew 6%, driven by 3% higher volume and 3% higher pricing. Growth was particularly robust in the Americas and Asia, Middle East & Africa, both up 8%, while Europe saw a 1% decline. By segment, Software & Systems led with 11% sales growth, fueled by strength in power, semiconductor, and aerospace & defense markets. Intelligent Devices grew 6%, supported by power and LNG demand, while Safety & Productivity rose 3%. Profitability improved, with diluted EPS from continuing operations rising 24% to $1.28. Adjusted diluted EPS reached $1.71, a 13% increase. Results were bolstered by $82 million in IEEPA tariff refunds, which positively impacted gross margins. Operating cash flow and free cash flow remain strong at $2.9 billion and $2.6 billion for the nine-month period, respectively. Management maintains a conservative capital structure, supported by a $2 billion revolving credit facility. For fiscal 2026, the company projects consolidated net sales growth of approximately 5% and adjusted diluted EPS of $6.55, with plans to return $2.2 billion to shareholders through dividends and share repurchases. |
| May 5, 2026 | mda_quarterly | Net sales for the second quarter of fiscal 2026 rose 3% to $4.6 billion, with adjusted diluted earnings per share increasing 4% to $1.54. Underlying sales growth of 0.5% was constrained by a 2% negative impact from software renewal timing and a 1% drag from the Middle East conflict. Gross margin declined 40 basis points to 53.1%, pressured by tariffs and software renewal timing, though the company may be eligible for IEEPA tariff refunds following a U.S. Supreme Court ruling. Within Software & Systems, Test & Measurement sales grew 16% driven by aerospace, defense, and semiconductor demand, while Control Systems & Software faced renewal timing headwinds despite strength in power and life sciences. Intelligent Devices sales grew 2%, with Americas-based power and LNG growth offsetting a 13% decline in China. Safety & Productivity sales rose 5% through pricing actions. The One Big Beautiful Bill Act increased the current effective tax rate but is expected to provide a benefit in fiscal 2027. For the full year 2026, the company forecasts net sales growth of approximately 4.5% and adjusted earnings per share between $6.45 and $6.55, with projected free cash flow of $3.5 to $3.6 billion. |
Source: SEC EDGAR filing text and events; period Aug 4, 2026; filed Aug 4, 2026.
EMR company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the research view.
A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.
A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.
A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.